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Abstract 
 
 
 
 
 
 
 
Tramadol is a centrally acting analgesic, atypical opioid, and although it is generally 
considered as a medicinal drug with a low potential for dependence, there is growing evidence of 
tramadol abuse in some countries. The ultraviolet detection is not suitable for analysis of tramadol in 
plasma, due to the lack of sensitivity and selectivity. However, it was shown that tramadol has a weak 
fluorescence, and the latest techniques for determination of tramadol in plasma include liquid 
chromatographic methods with fluorescence detection (FL). The objective of the paper was to 
develop a HPLC-FL method applicable for quantification of tramadol in human plasma.The 
separation was achieved by reverse phase HPLC method, using as stationary phase C18 – Kromasil® 
column and a mobile phase consisted of acetonitrile:0.1% formic acid (20:80). The fluorescence 
detection has been applied with λex/em= 280/310 nm.  A solid phase extraction procedure using C18 
cartridge was carried out.  
The linearity of the method has been demonstrated in the range of both therapeutic and toxic 
plasma tramadol levels (concentrations of 0.100 – 1µg/mL). The selectivity, precision, and accuracy 
of the method have been demonstrated. The limit of detection (LOD= 0.010 µg/mL) and the limit of 
quantification (LOQ = 0.100 µg/mL) have been established.The proposed method can be used to 
assess tramadol levels in human plasma in pharmacokinetic studies, as well as in overdose cases. The 
utility of the method for the quantification of therapeutic levels of tramadol has been shown on the 
plasma samples from the patients with tramadol treatment as analgesic (doses ranging from 100 mg 
to 400 mg/day).The developed method is rapid, using simple experimental conditions and an accurate 
and short extraction procedure. 
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Introduction 
The Tramadol is a central analgesic, atypical 
opioid, widely used in therapeutics, but frequently 
reported in cases of drug-related deaths (1). 
Therapeutic plasma concentrations, usually found 
after a 50-100 mg dose, can vary up to 0.3 µg/mL, 
while the toxic levels are generally around 1 
µg/mL. 
In general, HPLC methods, reported in 
literature, for quantification of tramadol, use the 
UV (at 280 nm) or fluorescence detection, and the 
separation is typically obtained on C-18 
(egPhenomonex® Gemini C-18, Hypersil® C18) 
columns. The mobile phases used contain 
phosphate buffer-methanol-acetonitrile (11) or 
35% acetonitrile and aqueous solution with 20mM 
sodium phosphate buffer, 30mMsodium dodecyl 
sulfate and 15mMtetraethylammonium bromide, 
pH 3.9 (2). 
Although tramadol has a core structure of 
benzene nucleus, UV detection is not suitable for 
its analysis in plasma, due to the lack of sensitivity 
and selectivity (3). 
Latest techniques for determination of 
tramadol include electrochemical methods (4), 
mass spectrometry (5), capillary electrophoresis 
(6) and HPLC with fluorescence detection (3, 7), 
the latter giving better selectivity and sensitivity. 
It has been shown that tramadol has a weak 
fluorescence, with a maximum of emission at 300 
nm, after excitation at 200 nm. In addition, the 
fluorescence spectrum of both parent drug and two 
major metabolites, O-desmethyltramadol and N-
desmethyltramadol are not virtually identical. 
Consequently, various publications reported 
different sensitivities of spectrofluorimetric or 
HPLC with fluorescence detection methods for the 
quantification of tramadol. 
Bahrami G. reported a HPLC method with 
fluorescence detection, involving pre-column 
derivatization with 9-fluorenylmethyl chloro 
formate, leading to increased fluorescence 
intensity of tramadoland an increase in detection 
and quantitation limits respectively (8). 
Gu Y et al. reported a HPLC method with 
fluorescence detection (wavelengths of excitation 
and emission of 275 and 300 nm) for 
quantification of tramadol and its active metabolite 
O-desmethyltramadolul in human plasma (2). A 
liquid-liquid extraction procedure was carried out 
using dichloromethane-diethyl ether-butanol 
(5:3:2), followed by extraction with sulfuric acid; 
tramadol, O-desmethyltramadol and internal 
standard, sotalol, were separated on a Hypersil® 
C18 column.  
Ebrahimzadeh H. and coworkers have 
developed a HPLC method with fluorescence 
detection (wavelengths of excitation and emission 
of 200 and 301nm respectively) to quantify 
tramadol and O-desmethyltramadol in human 
plasma and urine (9). Separation was achieved on a 
Baconi D. et al. 
RP-18e Chromolith® Performance column using as 
mobile phase methanol: water with phosphoric 
acid, at pH 2.5 (19:81). 
A HPLC method with fluorescence detection 
(excitation and emission wavelength of 200 nm 
and 295 nm) for determination of tramadol and O-
desmethyltramadol in plasma was proposed by 
Curticapean A. et al. working on a RP18column 
with C18 pre-column, with elution gradient over 
26 minutes, with the mobile phase consisting of 
phosphoric acid, triethylamine, methanol, 
acetonitrile (10). Liquid-liquid extraction with 
ethyl acetate and sotalol as internal standard were 
used. 
 Based on the literature data review 
regarding the methods of quantification of 
tramadol, mainly in biological samples, we have 
proposed the development of a HPLC method with 
sensitive fluorescence detection, rapid and suitable 
for routine clinical laboratories and forensic 
toxicology everyday use, in order to determine 
acute intoxication with tramadol. 
Materials and method 
Chemicals and apparatus: 
Reference standards and active substances: 
 Tramadol hydrochloride (Sigma Aldrich) 
Reagents: 
 Methanol Chromosolv for HPLC (Merck) 
 Acetonitrile Chromosolv for HPLC (Merck) 
 Formic acid (Merck) 
 Water for chromatogtaphic use (obtained 
with Barnstead®EasypureRoDi system) 
Materials 
 Solid phase extraction cartridges, DSC 18 
(Supelco) 
 Chromatographic column: Kromasil®, 150 
mm x 4.6 mm, 5 μm; C18stationary phase 
Apparatus: 
 Liquid-chromatograph Surveyor Plus 
(Thermo Electron Corp.), with the 
following modules: 
- DAD (diode array detector), with a 
specialized program for the determination 
of the spectral purity for eluted compounds 
- Fluorescence detector 
- Quaternary pump with vacuum degasser 
- Autosampler with thermostat (Peltier) 
- Column compartment with thermostat 
(Peltier) 
 Ultrasonic bath (Elmasonic S60 /Hmodel, 
Elma) 
 Analytical balance (Ohaus) 
 Evaporator under nitrogen stream (Techne 
Dry-Block  DB-3Dmodel, Bibby 
ScientíficInc.) 
 Solid phase extraction system (Visiprep 
Manifold model, Supelco) 
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 Refrigerated centrifuge Sigma 2-15 K (Sigma) 
Biological material 
 Human plasma obtained from peripheral venous 
blood provided by a Hematology Institute 
Methodology 
Chromatographic conditions 
 Mobile phase: 0.1% formic acid: acetonitrile 
(20:80) 
 Flow rate: 1 mL/min 
 Column temperature: 22°C  
 Sample temperature: 20°C 
 Fluorescence detector:   λ ex=  280 nm  and  λem= 
310 nm  
 Elution: isocratic 
 Injection volume: 20 µL 
 Analysis time : 6.5 minutes 
Preparation of solutions 
Tramadol stock solution: 10 mg of tramadol 
hydrochloride were quantitatively transferred into 
a 10 mL volumetric flask, dissolved in methanol 
and diluted to volume with the same solvent. 
Tramadol working solution (10 µg/mL) was 
prepared by dilution with mobile phase, from the 
stock solution. 
 
Control samples 
The „simulated” (spiked) human plasma 
controls were prepared at the following 
concentrations: 0.1 µg/mL, 0.5 µg/mL and 1 
µg/mL. 
Tramadol extraction procedure from plasma 
A solid phase extraction procedure was 
applied: at 1 mL plasma add 200 µLNaOH 0.1 
mol/L; the mixture is subject to vortex stirring for 
2 minutes, then it is slowly passed in the solid 
phase extraction system, over DSC 18cartridge, 
previously wetted with methanol (2 mL). 
Subsequently, the analyze is eluted from the 
cartridge with methanol (2 mL); the extract is 
centrifuged at 3000 rpm for 10 minutes, then it is 
evaporated to dryness under nitrogen stream. The 
residue was sampled in with 500 μL mobile phase, 
sonicated for 1-2 minute and then the samples 
obtained were injected into the HPLC system. 
Analytical method validation 
The method validation was carried out in 
accordance with FDA Guidance for Industry- 
Bioanalytical Method Validation, DRAFT 
guidance, 2013 (11). 
The experimental data was analyzed with 
Chromquest 4.2 data processing software. 
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Results 
Development and validation of the method 
In the elaboration of HPLC tramadol dosing 
method we start from the literature data, indicating 
the use of C18 chromatographic columns. 
Recommended mobile phases contain mostly 
acetonitrile or methanol, mixed with various buffer 
solutions (phosphate, triethylamine, acetate, formic 
acid) with pH between 2.5 and 7.3.  
The wavelengths of excitation and emission 
were typically 200/295, 301 or 275/300. Since the 
excitation wavelength of 200 nm is likely to be 
subject of much interference, and based on the 
absorption spectrum of tramadol with a peak at 
280 nm (12), we established the following 
experimental conditions for the fluorescence 
detection used for HPLC determination of 
tramadol: λex = 280 nm, λem = 310 nm. 
We selected the chromatographic column 
after testing three types of chromatography column 
with octadecylsilyl stationary phase 5 mm (C18): 
Symmetry® 3.9 mm x 150 mm, 4.6 mm x 150 mm, 
Kromasil®4.6 mm x 150 mm and Hypersil Gold® 
4.6 mm x 100 mm. Kromasil column provided 
suitable results in terms of analysis time. The 
retention time of tramadol is approximately 4.7 
min, in the working conditions, using a mixture of 
acetonitrile - 0.1% formic acid (20: 80), as mobile 
phase. We checked the possibility of using a 
simple mobile phase, containing methanol and 
0.2% formic acid solution in a 65:35 ratio; in these 
experimental conditions we cannot achieve an 
appropriate symmetry peak, and the retention time 
is very short (about 1,2 min.) and susceptible to 
interference with unretained compounds and 
plasma separated compounds.   
Given these results, we resorted to a mobile 
phase of acetonitrile and 0.1% formic acid, the 
proportions being determined by successive trials: 
30:70 (TR = 2.25 min.), 25:75 (TR = 2 , 5 min.), 
20:80 (TR = 4.65 min.). Based on these 
determinations, we selected a mobile phase of 
acetonitrile and 0.1% formic acid 20:80 (Figure1). 
We established the calibration curve using 
5 concentrations of tramadol hydrochloride 
solution in the concentration range of 0.1 µg / mL - 
1 µg / mL (0.1 µg / mL, 0.25 µg / mL, 0.5 µg / mL; 
0.75 µg / mL and 1 µg / mL). This concentrations 
 
Figure 1.Chromatogram of tramadol 
hydrochloride standard solution of 0.1 µg/ mL 
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domain coversboth therapeutic (from 0.1 to 0.3 µg 
/ mL) and toxic/lethal (1 µg / mL and 2 µg / mL) 
levelsof tramadol (13). Three replicate injections 
from each solution were performed. The 
experimental data well fitthe model of linear 
equations y = A + Bx, as we obtained aregression 
equation y = 1.70311e-007x - 0.00338394 with a 
correlation coefficient of 0.997414. 
 
Discussions  
The precision of the method was 
determined as repeatability in the linearity study of 
the method. Based on the results (analysis report 
provided by the software Chromquest 4.1, data not 
shown), the method proved to be precise (RSD ≤ 
2%). In addition, the intermediate precision was 
examined at threeconcentration levels, by 
determination carried out on different days; the 
experimental data are summarized in Table. 1. 
The detection and quantification limits were 
established based on the signal – noise ratio, by 
recording chromatograms and measuring the 
signals corresponding to reference solutions 
tramadol hydrochloride at concentrations of 0.01 
μg/mL - 1μg/mL.The value obtained for the limit 
of detection (DL) was of 10 ng / mL, while the 
limit of quantification (QL)was set at 100 ng/mL, a 
level at which both precision and accuracy have 
been determined. 
The specificity/selectivity of the method 
were determined by recording and comparing of 
the chromatograms of solutions obtained by 
processing plasma (blank), and plasma with the 
addition of tramadolhydrochloride (spiked 
plasma). 
The extraction from plasma samples was 
performed by solid phase technique (SPE), at 
alkaline pH, using DSC C18 extraction cartridges 
(Supelco). The chromatograms shown in the 
Figure 2 demonstrate the selectivity of the method; 
no other compound from plasma elutesat the 
retention time of analyze. Thus, the extraction 
procedure is appropriate regarding tramadol peak 
symmetry and separation from other plasma 
generated peaks.  
Table 1HPLC method for determination of 
tramadol hydrochloride - intermediate precision 
Tested 
concentration 
(μg/mL) 
Average 
concentration 
found (µg/mL) 
RSD (%) 
0.1 0.092 5.2 
0.5 0.45 3.78 
1.0 0.96 4.56 
Average - 4.51 
Baconi D. et al. 
The method accuracy, as average recovery, is 
within acceptance limits according to FDA 
guidelines. In our experiments we followed the 
possibility of a simple procedure of processing 
samples, involving only deproteinization with 
acetonitrile; however, this isolation 
method,although shorter regardinganalysis 
time,cannot be applied, as many interferenceswith 
the tramadol peak are obtained (possible 
endogenous compounds). 
Tramadol plasma dosing method in 
patients treated with tramadol  
Weverified the applicability of the HPLC 
method with fluorescence detection for the 
determination of tramadol in patients receiving 
tramadol, hospitalized at an Oncology Clinic from 
 Bucharest. Samples were obtained under the 
informed consent of the patients. 
Table 2. The accuracy (as percentage of recovery after extraction) of HPLC method for the 
determination of tramadol in plasma 
Concentration (µg/mL) 0.1 0.5 1.0 
Average recoveypercentage(%) 87.56 86.37 91.2 
Standard error 0.92 6.20 1.84 
Standard deviation 1.83 12.41 3.69 
CV 0,97% 6,98% 1,96% 
Averagerecovery: 88.37% 
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Figure 2. The selectivity of the HPLC method for 
determination of tramadol(blank plasma and plasma 
spiked with tramadol 0.5 µg/mL  - 2 samples, SPE 
extraction procedure) 
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Plasma samples were analyzed in 6 patients 
(5 women and one man) with cancer, treated with 
tramadol as an analgesic in doses ranging from 100 
mg to 400 mg/day, as tablets, capsules or injection. 
Experimental data indicate that tramadol 
has been identified in plasma in 5 of the 6 
patients;the plasma levels determined were in 
therapeutic range, 0.212 µg/mL, respectively 0.325 
µg/mL in 2 patients (Figure3); these patients 
received tramadol dose of 200 mg/day orally or 
300 mg / day injection (14). 
In samples obtained from  three patients, 
the quantification of tramadol could not be 
achieved as interferences were observed. There 
were other compounds extracted from the sample 
plasma that co-eluted with tramadol (data not 
shown). The results suggested a similar therapeutic 
scheme in the treatment of these three patients. 
The experimental results show that the 
developed HPLC method with fluorescence 
detection can be applied for determination of 
tramadol at therapeutic levels in plasma. In 
addition, the proposed extraction method - solid 
phase extraction, is simple, accurate and requires a 
shorter analysis time than liquid-liquid processes.  
Conclusions 
 Considering the native fluorescence of 
tramadol, and based on the literature data, 
we developed and validated a new HPLC 
method with fluorescence detection for the 
determination of tramadol in human 
plasma. 
 The method uses simple experimental 
conditions: Kromasil column (C18 bound 
phase), mobile phase acetonitrile: 0.1% 
formic acid, the fluorescence detection, 
λex/em = 280/310 nm for 6.5 minutes 
analysis time, applying SPE procedure 
from plasma on C18 cartridge. 
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Figure 3.Chromatograms obtained from 
plasma tramadol dosage in patients receiving 
tramadol (pacients 1 and 5) 
Baconi D. et al. 
 The developed method is selective, is linear 
on concentration range of 100 ng - 1 μg/
mL, corresponding to both therapeutic and 
the toxic/lethal tramadol levels, and has the 
detection/quantification limitsof 0.010 
μg/mL and 0. 100μg/mL respectively. In 
addition, the useof the fluorescence 
detector contributes, in itself, to increasing 
the selectivity of the method. 
 The applicability of HPLC-FL method was 
verified for determination of tramadol in 
plasma in patients treated with tramadol. 
Thus,the utility of the method for 
quantification of therapeutic levels of 
tramadol has been demonstrated. 
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